Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16012676 | 0.82 | HSD17B10 (0.41) | HSD17B10HRH3KMT2AHPGDBTK | |
| SCHEMBL6991986 | 0.82 | HSD17B10 (0.41) | HSD17B10HRH3KMT2AHPGDBTK | |
| SCHEMBL7419074 | 0.78 | HRH3 (0.37) | HRH3 | |
| SCHEMBL4344525 | 0.77 | HRH3 (0.38) | HRH3HPGDRECQLALDH1A1NPC1 | |
| SCHEMBL4337458 | 0.77 | HRH3 (0.38) | HRH3HPGDRECQLALDH1A1NPC1 | |
| SCHEMBL4344528 | 0.77 | HRH3 (0.38) | HRH3HPGDRECQLALDH1A1NPC1 | |
| SCHEMBL6600488 | 0.75 | SIGMAR1 (0.41) | HRH3HPGDSMN1; SMN2 | |
| SCHEMBL327357 | 0.75 | PREP (0.40) | HSD17B10HRH3KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL17025687 | 0.75 | HRH3 (0.35) | HRH3LMNAKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL25375745 | 0.74 | KMT2A (0.51) | KMT2ABTKTSHRMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018160521-A2 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Lazuli, Inc. (US) | 2018-09-07 | — | — | WO | disclosed |
| EP-2091534-A1 | AZETIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-27 | — | — | US | disclosed |
| WO-2008033465-A1 | AZETIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-0730454-A4 | ANTIARRHYTHMIC BENZODIAZEPINES | MERCK & CO INC (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-0907644-A4 | PHARMACEUTICAL PREPARATION | MERCK & CO INC (US) | 2003-02-05 | — | — | EP | disclosed |
| EP-0907644-A1 | PHARMACEUTICAL PREPARATION | Merck & Co., Inc. (US) | 1999-04-14 | — | — | EP | disclosed |
| US-5817658-A | ADMINISTERING A DIAZEPINE COMPOUND; DISEASES OF THE EAR | MERCK & COMPANY, INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5776930-A | CARDIOVASCULAR DISORDERS | MERCK & COMPANY, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1998000405-A1 | PHARMACEUTICAL PREPARATION | MERCK & CO., INC. (US) | 1998-01-08 | — | — | WO | disclosed |
| WO-1997049690-A1 | A METHOD FOR TREATING MENIERE'S DISEASE | MERCK & CO., INC. (US) | 1997-12-31 | — | — | WO | disclosed |
| US-5595990-A | TREATMENT OF CARDIOVASCULAR DISORDERS | MERCK & CO., INC. (US) | 1997-01-21 | — | — | US | disclosed |
| EP-0730454-A1 | ANTIARRHYTHMIC BENZODIAZEPINES | MERCK & CO. INC. (US) | 1996-09-11 | — | — | EP | disclosed |
| US-5426185-A | Antiarrhythmia agents having reduced side effects | MERCK & CO., INC. (US) | 1995-06-20 | — | — | US | disclosed |
| WO-1995014471-A1 | ANTIARRHYTHMIC BENZODIAZEPINES | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | LIPC, CES1, ZDHHC20 | HSD17B10 70/4885HRH3 2873/4885LMNA 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.